![](/wp-content/uploads/2018/10/Rk4NHzFLQdK8fd9pJMRr.png)
$599
Merck Q2 ’19 Earnings Update
Merck hosted its Q2 ’19 earnings call but did not provide any updates to its diabetes business beyond the Januvia and Steglatro financial performances. Unsurprisingly, the vast majority of the discussion was focused on Merck’s oncology and HIV portfolios. Below, FENIX provides diabetes-related highlights from the call.